Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology
PR Newswire —
TAIPEI, Oct. 31, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, announced the signing of a License Agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN's proprietary Val-Leu-Lys (VLK) linker technology in CDMO...
 
       
             
             
             
             
             
             
             
             
             
             
            